
Small Molecule Highlights

Snapshots from Recent Literature in Target-oriented Drug Design





MK-7845 CLpro Antiviral

Target: SARS-CoV-2 3C-like protease (CLpro)

Indication: SARS-CoV-2 infection

Inhibitor design: Structure based design and SAR optimization.


Activity: $3CL^{pro}$ WT IC₅₀ = 8.7 nM (biochemical), $3CL^{pro}$ P132H IC₅₀ = 15 nM (biochemical); A549 cell replicon IC₅₀ = 15 nM (cellular); Cytopathic effect

A549-ACE2-TMPRSS2 EC₅₀ = 444/351/215 nM in WA1/2020/Delta AY.2/Omicron B.1.1.529+R346K (cellular).

 $\label{eq:2.1} \begin{array}{l} ADME/PK: In vivo T_{1/2}=9.1/2.7/1.3 \ h \ in rat/dog/monkey; F(%)=90/70 \ in rat/dog; \\ CYP2B6 \ inhibition=7-12\% @ 20 \ \mu\text{M}; CYP3A4 \ inhibition=22-48\% @ 20 \ \mu\text{M}; \end{array}$ CYP3A (K_i/k_{inact} = 110 μ M/0.03 min⁻¹

In vivo: Outperformed nirmatrelvir in a mouse model of SARS-CoV-2 infection.

J. Med. Chem. Merck, USA



α-Syn & tau

тз Neurodegenerative Disease

Target: α-Synuclein (α-Syn) and tau

Indication: Alzheimer's disease and Parkinson's disease.

Inhibitor design: SAR for optimization of the linker and E3 requiting ligand. Activity: Tau $DC_{50} = 4.09 \ \mu$ M (cellular); a-Syn $DC_{50} = 1.57 \ \mu$ M (cellular); Cytoprotective effect @ 5 μ M in SH-SY5Y cells (cellular).


ADME/PK: In vivo Plasma $T_{1/2}$ = 3.24/3.78 in mouse/rat; Brain $T_{1/2}$ = 4.21 h in mouse;

CL_{plasma} = 0.1/0.12 L/h/kg in mouse/rat.

In vivo: Effectively decreased levels of a-Syn and tau protein aggregates and protected dopaminergic neurons from injury in an MPTP induced model of neurotoxic protein aggregation (8 mg/kg, i.v., mouse).

J. Med. Chem.

Sun Yat-sen University, China



JNJ-1802 Antiviral

Target: NS4B

Indication: Dengue Virus

NS4B

Inhibitor design: SAR optimization from lead scaffold.

Activity: EC₅₀ = 0.24/0.057/2.1/11 nM against DENV-1/DENV-2/DENV-3/DENV-4 (cellular).


ADMET/PK: F(%) = 108/58/51/50 in mouse/rat/dog/monkey; CL (mL/min/kg) = 4.97/4.9/6.4/2.45 in

mouse/rat/dog/monkey; hERG IC $_{\rm 50}$ > 30 μM ; Ames II was negative

In vivo: Dose-dependant decrease in viral RNA after 3 days in a murine model of DENV-2 infection. Viral RNA was undetectable in four of the seven mice treated with the highest dose (60 mg/kg, b.i.d.).

J. Med. Chem. Janssen, Belgium





Target: Burton's Tyrosine Kinase (BTK) and Ikaros family zinc finger protein 1/3 (IKZF1/3)

Indication: Various B-cell malignancies


Inhibitor design: SBDD and SAR.

Activity: BTK WT DC₅₀ = 4.5 nM (cellular); BTK C481S DC₅₀ = 31 nM (cellular); IKZF1 $\rm DC_{_{50}}$ = 57 nM (cellular); IKZF3 $\rm DC_{_{50}}$ = 36 nM (cellular).

ADMET/PK: F(%) = 36/7.1/1/1.2 in mouse/rat/dog/monkey; hERG IC₅₀ >30 μM; CYP IC₅₀ >30 μM (CYP3A4, CYP2D6, CYP2C9, CYP2C19, and CYP1A2)

In vivo: Near total TGI in BTK WT TMB8 xenograft mice (90 mg/kg, 5 day, QD, p.o., 25-day trial).

J. Med. Chem. Nurix Therapeutics, USA



|--|

Target: P-glycoprotein (P-gp)

Indication: Various oncology indications Inhibitor design: SAR optimization of previous scaffold. Activity: Cytotoxicity - %inhibition = 21.1/33.7 in MCF7/MCF7/ADR (cellular); Combination with doxorubicin - IC_{50} = 46.6 nM in MCF7/ARD (cellular).

Eur. J. Med. Chem

Zhejiang University, China